Perioperative Versorgung
Optimierung der Hämostase
Antifibrinolytika
Alternatives to allogeneic platelet transfusion. (öffnet neues Fenster)
Quelle: Br J Haematol 2016;175(3):381-92.
Tranexamic acid in patients undergoing noncardiac surgery. (öffnet neues Fenster)
Quelle: N Engl J Med. 2022;386(21):1986-97.
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. (öffnet neues Fenster)
Quelle: Cochrane Database Syst Rev 2011;(3):CD001886.
A single preoperative dose of tranexamic acid reduces perioperative blood loss: a meta-analysis. (öffnet neues Fenster)
Quelle: Ann Surg 2021;273(1):75-81.
Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. (öffnet neues Fenster)
Quelle: J Thorac Cardiovasc Surg 2013;145(1):234-40.
Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. (öffnet neues Fenster)
Quelle: BMJ 2012;344:e3054.
Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. (öffnet neues Fenster)
Quelle: Br J Surg 2013;100(10):1271-9.
Safety and efficacy of tranexamic acid in general surgery. (öffnet neues Fenster)
Quelle: JAMA Surg 2025;160(3):267-74.
Rekombinanter Faktor VIIa (rFVIIa)
Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa? (öffnet neues Fenster)
Quelle: Can J Anaesth 2006;53(4):353-6.
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (öffnet neues Fenster)
Quelle: Transfusion 2009;49 Suppl 5:240S-7S.
Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. (öffnet neues Fenster)
Quelle: Circulation 2008;118(4):331-8.
Recombinant factor VIIa as last-resort treatment of desperate haemorrhage. (öffnet neues Fenster)
Quelle: Acta Anaesthesiol Scand 2012;56(5):636-44.
Gerinnungsfaktorenkonzentrate
Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. (öffnet neues Fenster)
Quelle: Ann Thorac Surg 2009;88(5):1666-8.
Bloodless orthotopic heart transplantation in a Jehovah's Witness. (öffnet neues Fenster)
Quelle: A A Case Rep 2015;4(10):140-2.
Fibrinogen replacement therapy: a critical review of the literature. (öffnet neues Fenster)
Quelle: Blood Transfus 2012;10(1):23-7.
First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. (öffnet neues Fenster)
Quelle: Anesthesiology 2011;115(6):1179-91.
Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. (öffnet neues Fenster)
Quelle: Thromb Haemost 2009;102(1):137-44.
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. (öffnet neues Fenster)
Quelle: Transfusion 2014;54(5):1389-405.
Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. (öffnet neues Fenster)
Quelle: Anesthesiology 2013;118(1):40-50.
Desmopressin
Viskoelastische Tests zur Identifizierung chirurgischer oder koagulopathischer Blutungen
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. (öffnet neues Fenster)
Quelle: Eur J Anaesthesiol 2013;30(6):270-382.
